GlassScriptPhysician profile
Darius J Adams
NPI 1972506749
$22,318.30
in general payments reported to CMS, 2019-2025
21 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,388 · 2021: $110 · 2022: $58.41 · 2023: $190 · 2024: $2,396 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,560 · Food and Beverage: $1,362 · Education: $35.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,560.18 |
| Food and Beverage | $1,361.94 |
| Education | $35.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $9,974.04 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $3,451.25 | 2019 | |
| Amicus Therapeutics, INC. | $3,341.04 | 2019-2025 | |
| Horizon Therapeutics Plc | $2,345.57 | 2019 | |
| Modernatx, INC. | $1,975.04 | 2024 | |
| Genzyme Corporation | $668.80 | 2019-2025 | |
| Chiesi USA, INC. | $137.90 | 2024-2025 | Elfabrio |
| Takeda Pharmaceuticals U.S.A., INC. | $132.34 | 2020-2025 | Vpriv |
| Strongbridge US INC. | $55.76 | 2020 | |
| Alexion Pharmaceuticals, INC. | $52.42 | 2019-2025 | Strensiq |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $44.61 | 2020-2023 | Zolgensma |
| Ptc Therapeutics, INC. | $35.07 | 2025 | Sephience |
| Biogen, INC. | $28.15 | 2020 | |
| Springworks Therapeutics, INC. | $24.16 | 2025 | Gomekli |
| Ns Pharma, INC. | $23.97 | 2024 | Viltepso |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $14.20 | 2020 | |
| Akcea Therapeutics, INC. | $13.98 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darius Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.